MRM Health
- Biotech or pharma, therapeutic R&D
MRM Health is a venture-backed clinical-stage biotech developing innovative live biotherapeutics for inflammatory, oncology, CNS, and metabolic diseases. Its lead program, MH002, is advancing toward late-stage clinical development in Ulcerative Colitis and Pouchitis, following positive Phase 2a results.
Powered by its disruptive CORAL® technology, MRM Health designs microbiome-based therapeutics using optimized consortia of 5 to 10 gut bacteria, manufactured through a single, standardized, and scalable process. Beyond its clinical IBD program, the company has a preclinical pipeline in immuno-oncology and autoimmune diseases, plus a partnered asset in metabolic disorders (MASH).
A VIB spin-off, MRM Health is backed by leading investors, including Ackermans & van Haaren, OMX Europe Venture Fund, SFPIM, Qbic fund, and VIB and has strategic partnerships with VIB, IFF (Dupont) and Evonik.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}